
Bisher Sawaf, MD
@bishersawaf
🇸🇾GI enthusiaast, PGY1-IM & MPH @UToledoIM, & @NIH @PPCR_Course 🇺🇸 | PGY4-IM @HMC_Qatar 🇶🇦 | Postdoc fellow @AUBMC_official 🇱🇧 | MCRP @DIU_Dresden🇩🇪
ID: 974044963
https://www.linkedin.com/in/bisher-sawaf-8b5333107/ 27-11-2012 14:52:28
289 Tweet
837 Takipçi
1,1K Takip Edilen


Another small step toward the GI. I am lucky to have such great colleagues Shahem Abbarh, MBBS, MRCP(UK) Mhd Kutaiba Albuni, M.D Thanks ACG for this recognition.



Presenting abstracts & enjoying our time at OGS, meeting my colleagues from UT and my dear Syrian friends 😊 Ohio Gastroenterology Society University of Toledo Internal Medicine Residency #SyrianFriends Shahem Abbarh, MBBS, MRCP(UK) Mhd Kutaiba Albuni, M.D Yusuf Hallak







A great opportunity to attend #CCCongress25 to present our abstracts with Shahem Abbarh, MBBS, MRCP(UK) and connect with leaders in this growing field. Grateful for the insights and great people who i met here, loving the San Francisco vibes! #IBD #AGA #MedTwitter


hrilled to see our team's hard work pay off such a massive achievement! Grateful to all friends, fellows, and mentors across the U.S. who collaborated to reach our goals. Huge shoutout to the IM-UTMC group for their incredible effort! #DDW2025 #GITwitter University of Toledo Internal Medicine Residency Gastroenterology

#DDW2025 🥊Real-world outcomes RISA vs OTHER at yr2 in #Crohns Digestive Disease Week 🥊RISA vs UST: 👍🏼RISA ✅At 12 mos:⬇️PO predn use & 🏥 ✅At 24 mos: ⬇️Odds of major SB & colon✂️ 🥊RISA vs TNFi ✅At 12 months & 24 months: ⬇️Odds of PO predn on RISA



📢 Just out! Our meta-analysis comparing adalimumab vs infliximab in perianal Crohn’s disease (6 studies, n=590): No significant difference in clinical or radiologic healing.✅ Adalimumab is non-inferior to infliximab! Huge thanks to David T. Rubin, MD (Dr. David T. Rubin)! #IBD #Crohns

Newly published In IBD, choosing between anti-TNF and anti-IL-12/23 is like picking your fighter turns out, both pack a punch. 💥 New data suggests anti-IL-12/23 holds its own, even in TNF-naïve patients. #IBD #GI #MedTwitter 📖 karger.com/iid/article/do…” Miguel Regueiro


